S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
NASDAQ:ALNY

Alnylam Pharmaceuticals - ALNY Price Target & Analyst Ratings

$233.85
+4.46 (+1.94%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$228.03
$236.80
50-Day Range
$127.70
$233.85
52-Week Range
$117.58
$236.80
Volume
614,186 shs
Average Volume
897,815 shs
Market Capitalization
$28.07 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$227.29

Alnylam Pharmaceuticals Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 17 Analyst Ratings

Consensus Analyst Price Target

$227.29
-2.80% Downside
High Prediction$430.00
Average Prediction$227.29
Low Prediction$98.00
TypeCurrent
8/13/21 to 8/13/22
1 Month Ago
7/14/21 to 7/14/22
3 Months Ago
5/15/21 to 5/15/22
1 Year Ago
8/13/20 to 8/13/21
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
12 Buy rating(s)
13 Buy rating(s)
14 Buy rating(s)
7 Buy rating(s)
Hold
5 Hold rating(s)
5 Hold rating(s)
3 Hold rating(s)
8 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$227.29$213.59$219.76$168.60
Predicted Upside-2.80% Downside31.60% Upside31.68% Upside3.34% Upside
Get Alnylam Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter.


ALNY Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ALNY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Alnylam Pharmaceuticals Stock vs. The Competition

TypeAlnylam PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.71
2.71
2.50
Consensus RatingModerate BuyBuyHold
Predicted Upside-2.80% Downside722.45% Upside13.81% Upside
News Sentiment RatingPositive News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
1038
78.28%
Underperform Votes
288
21.72%
Avg. Outperform Votes
167
66.80%
Avg. Underperform Votes
83
33.20%
Avg. Outperform Votes
840
68.74%
Avg. Underperform Votes
382
31.26%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/9/2022Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$252.00+11.20%
8/4/2022BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform$166.00 ➝ $192.00-13.62%
8/4/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight$159.00 ➝ $225.00+0.88%
8/4/2022Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Keay Nakae
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy$200.00 ➝ $250.00+17.92%
8/4/2022Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Joseph Stringer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy$205.00 ➝ $240.00+13.20%
8/4/2022Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$206.00 ➝ $280.00+32.07%
7/12/2022Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$175.00+19.99%
6/27/2022Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
6/15/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform$96.00 ➝ $98.00-26.60%
6/7/2022William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Minter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
5/2/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Patrick Trucchio
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Target$400.00 ➝ $430.00+222.27%
4/6/2022Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform$205.00+28.20%
3/24/2022Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$215.00+33.00%
1/3/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$211.00+23.41%
1/3/2022Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Overweight$181.00 ➝ $208.00+22.66%
11/22/2021The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$273.00+50.83%
11/22/2021Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeSector Perform ➝ Outperform$144.00 ➝ $225.00+24.31%
10/4/2021UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$141.00 ➝ $215.00+11.58%
8/4/2021Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$196.00 ➝ $216.00+20.80%
1/13/2021Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetIn-Line ➝ Outperform$154.00 ➝ $197.00+18.64%
9/30/2020Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$145.00-0.01%
5/7/2020JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Neutral$133.00 ➝ $137.00-5.69%
4/14/2020Nomura Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetReduce$75.00 ➝ $74.00-37.82%
12/17/2019Piper Jaffray Companies
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Edward Tenthoff
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight$145.00 ➝ $155.00+32.99%
(Data available from 8/13/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












ALNY Price Target - Frequently Asked Questions

What is Alnylam Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 17 analysts in the last year, the consensus rating for Alnylam Pharmaceuticals stock is Moderate Buy based on the current 5 hold ratings and 12 buy ratings for ALNY. The average twelve-month price prediction for Alnylam Pharmaceuticals is $227.29 with a high price target of $430.00 and a low price target of $98.00. Learn more on ALNY's analyst rating history.

Do Wall Street analysts like Alnylam Pharmaceuticals more than its competitors?

Analysts like Alnylam Pharmaceuticals less than other Medical companies. The consensus rating for Alnylam Pharmaceuticals is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how ALNY compares to other companies.

Do MarketBeat users like Alnylam Pharmaceuticals more than its competitors?

MarketBeat users like Alnylam Pharmaceuticals more than other Medical companies. 78.28% of MarketBeat users gave Alnylam Pharmaceuticals an outperform vote while medical companies recieve an average of 66.80% outperform votes by MarketBeat users.

Is Alnylam Pharmaceuticals being downgraded by Wall Street analysts?

Over the previous 90 days, Alnylam Pharmaceuticals's stock had 1 downgrade by analysts.

Does Alnylam Pharmaceuticals's stock price have much upside?

According to analysts, Alnylam Pharmaceuticals's stock has a predicted upside of 26.20% based on their 12-month price targets.

What analysts cover Alnylam Pharmaceuticals?

Stock Ratings Reports and Tools

This page (NASDAQ:ALNY) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.